Sio Capital Management LLC Sells 5,380 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Sio Capital Management LLC reduced its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 1.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 504,887 shares of the biotechnology company’s stock after selling 5,380 shares during the quarter. Astria Therapeutics accounts for 2.2% of Sio Capital Management LLC’s portfolio, making the stock its 16th largest position. Sio Capital Management LLC’s holdings in Astria Therapeutics were worth $5,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ATXS. Quest Partners LLC lifted its holdings in Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Astria Therapeutics during the third quarter worth $155,000. Hsbc Holdings PLC bought a new position in Astria Therapeutics in the second quarter valued at about $171,000. Price T Rowe Associates Inc. MD acquired a new stake in Astria Therapeutics in the first quarter worth about $200,000. Finally, Intech Investment Management LLC bought a new stake in Astria Therapeutics during the 3rd quarter worth about $228,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

Astria Therapeutics Stock Up 1.9 %

Shares of NASDAQ ATXS opened at $10.50 on Friday. The company has a fifty day moving average price of $11.18 and a 200 day moving average price of $10.62. Astria Therapeutics, Inc. has a 1-year low of $4.50 and a 1-year high of $16.90.

Analysts Set New Price Targets

ATXS has been the topic of several recent research reports. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research report on Thursday, November 14th. Finally, Oppenheimer upped their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics currently has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.